Ferring Pharmaceuticals joins the Foundation for Technological Innovation
Founded in 1950, the multinational biopharmaceutical company Ferring Pharmaceuticals has joined the Foundation for Technological Innovation (FIT) in September. With its international headquarters in Saint-Prex (Vaud), Ferring is at the heart of life sciences innovation in Western Switzerland and will join local players in supporting local innovation. Ferring has also become a member of the FIT Foundation Board as well as the Tech Seed and Tech Growth Committees.
Since its creation in 1994, FIT has supported over 240 startups with over 36% of them active in life sciences, thereby building a strong bond with innovation fields such as biotech, medtech, healthtech or even digital health. With CHUV, UNIL and EPFL among its members, the Foundation is well connected to the academic side of life-sciences innovation and very pleased to now welcome complementary expertise from a multinational company. “Ferring is a world-class leader in reproductive medicine and maternal health, gastroenterology and urology. We are thrilled to connect our startups with a company of this magnitude” says David Kappeler, Head of Investments at FIT.
With its head office in Saint-Prex, three sites in Switzerland and 56 offices worldwide, Ferring has an extensive expertise in Research & Development. Henri Kornmann explains: “Ferring is a research-driven, specialty biopharmaceutical group committed to apply new science to unmet needs”. By joining the Foundation, Ferring intends to strengthen its ties with the local ecosystem in French-speaking Switzerland and to connect with other key-players in innovation. “We already have good links with the life sciences campus Biopôle through our Biologics Innovation Centre and joining FIT enables us to participate to the success of many talented entrepreneurs” Henri Kornmann adds. At the heart of the so-called “Health Valley”, supporting young innovative companies contributes to the dynamism of the already rich innovation network and to the area’s economic prosperity.
Ferring’s Director of Biologics Development, Henri Kornmann, has both joined the Foundation board and the Selection Committee for Tech Growth loans, and Kristin Wannerberger, Director R&D Alliance Management, is now a member of the FIT Tech Seed Selection Committee.
About the Foundation for technological innovation (FIT)
Founded in the canton of Vaud in 1994, the FIT is a non-profit organisation that encourages entrepreneurship, supports innovation and helps to boost the local economy by providing loans and grants to young companies. The funding is aimed at start-ups in Vaud and French-speaking Switzerland, innovating either by their technological content or by their business model.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries, and markets its products in 110 countries.